Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 40Carcinoma, Transitional Cell 3Muscle Invasive Bladder Cancer 2Infiltrating Bladder Urothelial Carcinoma 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Ureteral Neoplasms 1Transitional Cell Carcinoma of the Bladder 1Transitional Cell Bladder Cancer 1Stage 0is Bladder Urothelial Carcinoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-metastatic Muscle Invasive Bladder Cancer 1Invasive Bladder Cancer 1Ileus 1Cone Dystrophy 3 1Bladder Adenocarcinoma 1Adrenal Gland Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Carboplatin 4Sunitinib 3Pemetrexed 3Mitomycin 3cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urologic Neoplasms × Cystectomy × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡